Huntington's Disease Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Spark therapeutics, Chong Kun Dang Pharma, Neuvivo, UniQure Biopharma, Wave Life S

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Huntington's Disease pipeline constitutes 50+ key companies continuously working towards developing 50+ Huntington's Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Huntington's Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Huntington's Disease Market.

The Huntington's Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Huntington's Disease Pipeline Report:
https://www.delveinsight.com/sample-request/huntingtons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Huntington's Disease treatment therapies with a considerable amount of success over the years.
• Huntington's Disease companies working in the treatment market are Sangamo Therapeutics, Spark therapeutics, Chong Kun Dang Pharmaceutical, Neuvivo, UniQure Biopharma, Wave Life Sciences, Novartis, Sage Therapeutics, Annexon, Neurocrine Biosciences, Prilenia Therapeutics, and others, are developing therapies for the Huntington's Disease treatment
• Emerging Huntington's Disease therapies in the different phases of clinical trials are- TAK-686, Huntington's Disease therapy, CKD-504, NP 001, rAAV5-miHTT, WVE003, Branaplam, SAGE-718, ANX005, Valbenazine, Pridopidine, and others are expected to have a significant impact on the Huntington's Disease market in the coming years.
• In December 2023, uniQure N.V. (NASDAQ: QURE), a prominent gene therapy firm dedicated to developing groundbreaking treatments for individuals with critical medical conditions, has unveiled revised interim findings, encompassing a follow-up period of up to 30 months, from 39 participants engaged in the continuing Phase I/II clinical trials of AMT-130 aimed at addressing Huntington's disease in both the United States and Europe.
• In August 2022, In order to undertake a Phase I/II trial for its innovative Huntington's Disease (HD) gene treatment, BV-101, through its subsidiary BrainVectis in France, Asklepios BioPharmaceutical, a fully owned and independently run subsidiary of Bayer AG, got approval. The National Agency for Safety of Medicines and Health Products (ANSM), the nation's regulatory drug agency, has granted the corporation permission to start seeking volunteers after the relevant Ethics Committee approved the trial protocol.
• In March 2022, The PIVOT-HD Phase II clinical trial investigating PTC518 in patients with Huntington's disease (HD) has begun, according to PTC Therapeutics. An international trial called PIVOT-HD is beginning in the US. PTC518 is a small chemical splicing modifier that may be taken orally and was created specifically to reduce huntingtin mRNA and protein. The underlying cause of HD is not currently being treated.
• In January 2022, A new Phase II trial to assess tominersen in Huntington's disease (HD) has been planned, according to an announcement by Ionis Pharmaceuticals and its partner Roche. Tominersen may benefit younger adult patients with reduced disease load, according to exploratory posthoc analysis conducted after treatment in the Phase III GENERATION HD1 study was stopped. It is necessary to confirm these findings in a randomised, placebo-controlled trial.

Huntington's Disease Overview
Huntington's disease is a hereditary neurological disorder characterized by progressive degeneration of brain cells, particularly in areas associated with movement, cognition, and behavior. It is caused by a mutation in the HTT gene, leading to the production of abnormal huntingtin protein aggregates in the brain. Symptoms typically manifest in adulthood and worsen over time, including involuntary movements (chorea), cognitive decline, psychiatric symptoms, and impaired motor function.

Get a Free Sample PDF Report to know more about Huntington's Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/huntingtons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Huntington's Disease Drugs Under Different Phases of Clinical Development Include:
• TAK-686: Sangamo Therapeutics
• Huntington's Disease therapy: Spark therapeutics
• CKD-504: Chong Kun Dang Pharmaceutical
• NP 001: Neuvivo
• rAAV5-miHTT: UniQure Biopharma
• WVE003: Wave Life Sciences
• Branaplam: Novartis
• SAGE-718: Sage Therapeutics
• ANX005: Annexon
• Valbenazine: Neurocrine Biosciences
• Pridopidine: Prilenia Therapeutics

Huntington's Disease Route of Administration
Huntington's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Huntington's Disease Molecule Type
Huntington's Disease Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Huntington's Disease Pipeline Therapeutics Assessment
• Huntington's Disease Assessment by Product Type
• Huntington's Disease By Stage and Product Type
• Huntington's Disease Assessment by Route of Administration
• Huntington's Disease By Stage and Route of Administration
• Huntington's Disease Assessment by Molecule Type
• Huntington's Disease by Stage and Molecule Type

DelveInsight's Huntington's Disease Report covers around 50+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Huntington's Disease product details are provided in the report. Download the Huntington's Disease pipeline report to learn more about the emerging Huntington's Disease therapies at:
https://www.delveinsight.com/sample-request/huntingtons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Huntington's Disease Therapeutics Market include:
Key companies developing therapies for Huntington's Disease are - Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, SAGE Therapeutics, PTC Therapeutics, WaVe life Sciences, Novartis, Neurimmune Therapeutics, SOLA Biosciences, UniQure Biopharma, Roche, Annexon, Inc., Azevan Pharmaceuticals, SOM Innovation Biotech SA, Asklepios BioPharmaceutical, Luye Pharma Group Ltd., BrainStorm Cell Therapeutics, Voyager Therapeutics, Passage Bio, Locana Bio, Ceptur Therapeutics, Enzerna Biosciences, AFFiRiS AG, Arvinas, Atalanta Therapeutics, Anima Biotech, and others.

Huntington's Disease Pipeline Analysis:
The Huntington's Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Huntington's Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Huntington's Disease Treatment.
• Huntington's Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Huntington's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Huntington's Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Huntington's Disease drugs and therapies-
https://www.delveinsight.com/sample-request/huntingtons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Huntington's Disease Pipeline Market Drivers
• Introduction of disease-modifying drugs, further understanding in pathogenesis are some of the important factors that are fueling the Huntington's Disease Market.

Huntington's Disease Pipeline Market Barriers
• However, lesser approved therapies, stringent regulations and other factors are creating obstacles in the Huntington's Disease Market growth.

Scope of Huntington's Disease Pipeline Drug Insight
• Coverage: Global
• Key Huntington's Disease Companies: Sangamo Therapeutics, Spark therapeutics, Chong Kun Dang Pharmaceutical, Neuvivo, UniQure Biopharma, Wave Life Sciences, Novartis, Sage Therapeutics, Annexon, Neurocrine Biosciences, Prilenia Therapeutics, and others
• Key Huntington's Disease Therapies: TAK-686, Huntington's Disease therapy, CKD-504, NP 001, rAAV5-miHTT, WVE003, Branaplam, SAGE-718, ANX005, Valbenazine, Pridopidine, and others
• Huntington's Disease Therapeutic Assessment: Huntington's Disease current marketed and Huntington's Disease emerging therapies
• Huntington's Disease Market Dynamics: Huntington's Disease market drivers and Huntington's Disease market barriers

Request for Sample PDF Report for Huntington's Disease Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/huntingtons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Huntington's Disease Report Introduction
2. Huntington's Disease Executive Summary
3. Huntington's Disease Overview
4. Huntington's Disease- Analytical Perspective In-depth Commercial Assessment
5. Huntington's Disease Pipeline Therapeutics
6. Huntington's Disease Late Stage Products (Phase II/III)
7. Huntington's Disease Mid Stage Products (Phase II)
8. Huntington's Disease Early Stage Products (Phase I)
9. Huntington's Disease Preclinical Stage Products
10. Huntington's Disease Therapeutics Assessment
11. Huntington's Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Huntington's Disease Key Companies
14. Huntington's Disease Key Products
15. Huntington's Disease Unmet Needs
16 . Huntington's Disease Market Drivers and Barriers
17. Huntington's Disease Future Perspectives and Conclusion
18. Huntington's Disease Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:
Huntington's Disease Market
https://www.delveinsight.com/report-store/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Huntington's Disease Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Huntington's Disease Epidemiology
https://www.delveinsight.com/report-store/huntingtons-disease-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Huntington's Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Iga Nephropathy Market
https://www.delveinsight.com/report-store/iga-nephropathy-market
DelveInsight's "IgA Nephropathy Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of the IgA Nephropathy, historical and forecasted epidemiology as well as the IgA Nephropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China.

Vutrisiran Market
https://www.delveinsight.com/report-store/vutrisiran-market
DelveInsight's "Vutrisiran Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Vutrisiran, historical and forecasted epidemiology as well as the Vutrisiran market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Gastroesophageal Reflux Disease Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market
DelveInsight's "Gastroesophageal Reflux Disease (GERD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Gastroesophageal Reflux Disease (GERD), historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease (GERD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.